CHA has released the attached summary, prepared by Health Policy Alternatives, Inc., detailing the 340B omnibus guidance released Aug. 28 by the Health Resources and Services Administration (HRSA). The notice with comment period provides guidance for covered entities enrolled in the 340B program and drug manufacturers required by section 340B of the Public Health Service Act to make their drugs available to covered entities under the 340B program.
This content is restricted to members.
